DCF Advisers’s Altimmune ALT Stock Holding History

DCF Advisers’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$114K	Sell	37,000 -121,000	-77%	-$514K	0.03%	85
2025 Q4	$570K	Buy	+158,000	New	+$689K	0.15%	80
2025 Q3	–	Sell	-126,000	Closed	-$488K	–	96
2025 Q2	$488K	Buy	126,000 +31,000	+33%	+$168K	0.23%	69
2025 Q1	$475K	Buy	+95,000	New	+$602K	0.23%	68
2024 Q4	–	Sell	-57,000	Closed	-$350K	–	89
2024 Q3	$350K	Sell	57,000 -51,000	-47%	-$346K	0.14%	78
2024 Q2	$718K	Sell	108,000 -13,000	-11%	-$95.9K	0.37%	56
2024 Q1	$1.23M	Buy	121,000 +17,000	+16%	+$173K	0.61%	39
2023 Q4	$1.17M	Buy	104,000 +5,000	+5%	+$20.9K	0.63%	39
2023 Q3	$257K	Sell	99,000 -35,000	-26%	-$100K	0.14%	80
2023 Q2	$473K	Hold	134,000	–	–	0.25%	63
2023 Q1	$565K	Sell	134,000 -15,000	-10%	-$178K	0.35%	45
2022 Q4	$2.45M	Buy	149,000 +126,500	+562%	+$1.42M	1.66%	18
2022 Q3	$287K	Buy	+22,500	New	+$332K	0.19%	64

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DCF Advisers's ALT Position: Q1 2026 in Review

DCF Advisers reduced its Altimmune (ALT) stake by 21% in Q1 2026, selling an estimated $17K and leaving 14,700 shares worth $45.3K. The position accounts for 0.01% of the portfolio, ranked #86.

DCF Advisers first reported a position in ALT in Q2 2021 and has held it in 18 quarters since. The position peaked at $3.92M in Q2 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

DCF Advisers held 14,700 shares of Altimmune worth $45.3K as of Q1 2026.
DCF Advisers sold 4,000 Altimmune shares in Q1 2026, an estimated $17K.
Altimmune made up 0.01% of DCF Advisers's portfolio in Q1 2026, its #86 holding.
DCF Advisers first reported a position in Altimmune in Q2 2021 and has held it in 18 quarters since.
DCF Advisers's Altimmune position peaked at $3.92M in Q2 2022.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.